- Home
- INAB vs KPRX Comparison
INAB vs KPRX Comparison
Compare INAB & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- KPRX
- Stock Information
- Founded
- INAB 2016
- KPRX 1998
- Country
- INAB United States
- KPRX United States
- Employees
- INAB N/A
- KPRX N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- INAB Health Care
- KPRX Health Care
- Exchange
- INAB Nasdaq
- KPRX Nasdaq
- Market Cap
- INAB 7.5M
- KPRX 8.7M
- IPO Year
- INAB 2021
- KPRX N/A
- Fundamental
- Price
- INAB $2.26
- KPRX $2.73
- Analyst Decision
- INAB Strong Buy
- KPRX Strong Buy
- Analyst Count
- INAB 2
- KPRX 1
- Target Price
- INAB $108.00
- KPRX $10.00
- AVG Volume (30 Days)
- INAB 92.2K
- KPRX 87.0K
- Earning Date
- INAB 08-07-2025
- KPRX 08-08-2025
- Dividend Yield
- INAB N/A
- KPRX N/A
- EPS Growth
- INAB N/A
- KPRX N/A
- EPS
- INAB N/A
- KPRX N/A
- Revenue
- INAB N/A
- KPRX N/A
- Revenue This Year
- INAB N/A
- KPRX N/A
- Revenue Next Year
- INAB N/A
- KPRX N/A
- P/E Ratio
- INAB N/A
- KPRX N/A
- Revenue Growth
- INAB N/A
- KPRX N/A
- 52 Week Low
- INAB $1.98
- KPRX $2.25
- 52 Week High
- INAB $17.64
- KPRX $4.29
- Technical
- Relative Strength Index (RSI)
- INAB 47.63
- KPRX 50.64
- Support Level
- INAB $2.10
- KPRX $2.27
- Resistance Level
- INAB $2.46
- KPRX $3.01
- Average True Range (ATR)
- INAB 0.14
- KPRX 0.17
- MACD
- INAB 0.02
- KPRX 0.03
- Stochastic Oscillator
- INAB 56.12
- KPRX 62.16
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.